EE374 Budget Impact of Adalimumab Sandoz (BIOSIMILAR) in Comparison to Adalimumab- Reference Product in the Management of Autoimmune Diseases in Dubai

Abstract

Authors

M Farghaly MA Sara Ahmad Y Sharma SS Sultana O Mohammed

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×